The National Cancer Institute publishes the Comprehensive Cancer Control Branch Program Evaluation Toolkit. On pages 25–29, the discussion centers on the identification and engagement of stakeholders.
https://www.cdc.gov/cancer/ncccp/prog_eval_toolkit.htm
What additional stakeholders might be valuable participants in the evaluation? What would they want to know?
Could this toolkit be transitioned to other disease prevention programs? If so, would the stakeholders be drastically different? Why or why not?
Include your own experience as well as 2 citations that align with or contradict your comments as sourced from peer-reviewed academic journals, industry publications, books, and/or other sources. Cite your sources using APA formatting. If you found information that contradicts your experience, explain why you agree or disagree with the information.